0 19 Platelet-activating platelet-activating JJ 20 26 factor factor NN 27 34 induces induce VBZ 35 47 phospholipid phospholipid JJ 48 56 turnover turnover NN 56 57 , , , 58 65 calcium calcium NN 66 70 flux flux NN 70 71 , , , 72 83 arachidonic arachidonic JJ 84 88 acid acid NN 89 99 liberation liberation NN 99 100 , , , 101 111 eicosanoid eicosanoid NN 112 122 generation generation NN 122 123 , , , 124 127 and and CC 128 136 oncogene oncogene NN 137 147 expression expression NN 148 150 in in IN 151 152 a a DT 153 158 human human JJ 159 160 B B NNP 161 165 cell cell NN 166 170 line line NN 170 171 . . . 173 192 Platelet-activating platelet-activating JJ 193 199 factor factor NN 200 202 is be VBZ 203 204 a a DT 205 211 potent potent JJ 212 220 mediator mediator NN 221 223 of of IN 224 227 the the DT 228 240 inflammatory inflammatory JJ 241 249 response response NN 249 250 . . . 251 258 Studies study NNS 259 261 of of IN 262 265 the the DT 266 273 actions action NNS 274 276 of of IN 277 296 platelet-activating platelet-activating JJ 297 303 factor factor NN 304 308 have have VBP 309 317 centered center VBN 318 324 mainly mainly RB 325 331 around around IN 332 343 neutrophils neutrophil NNS 343 344 , , , 345 354 monocytes monocyte NNS 354 355 , , , 356 359 and and CC 360 369 platelets platelet NNS 369 370 . . . 371 373 In in IN 374 378 this this DT 379 385 report report NN 386 388 we we PRP 389 394 begin begin VBP 395 397 to to TO 398 405 uncover uncover VB 406 409 the the DT 410 419 influence influence NN 420 422 of of IN 423 442 platelet-activating platelet-activating JJ 443 449 factor factor NN 450 452 on on IN 453 454 B B NNP 455 466 lymphocytes lymphocyte NNS 466 467 . . . 468 477 Employing employ VBG 478 481 the the DT 482 497 EBV-transformed ebv-transformed JJ 498 503 human human JJ 504 505 B B NNP 506 510 cell cell NN 511 515 line line NN 516 522 SKW6.4 skw6.4 NN 522 523 , , , 524 526 we we PRP 527 538 demonstrate demonstrate VBP 539 543 that that IN 544 563 platelet-activating platelet-activating JJ 564 570 factor factor NN 571 584 significantly significantly RB 585 591 alters alter VBZ 592 600 membrane membrane NN 601 613 phospholipid phospholipid NN 614 624 metabolism metabolism NN 625 634 indicated indicate VBN 635 637 by by IN 638 641 the the DT 642 655 incorporation incorporation NN 656 658 of of IN 659 662 32P 32p NN 663 667 into into IN 668 687 phosphatidylcholine phosphatidylcholine NN 687 688 , , , 689 709 phosphatidylinositol phosphatidylinositol NN 709 710 , , , 711 714 and and CC 715 727 phosphatidic phosphatidic JJ 728 732 acid acid NN 733 736 but but CC 737 740 not not RB 741 754 significantly significantly RB 755 759 into into IN 760 784 phosphatidylethanolamine phosphatidylethanolamine NN 785 787 at at IN 788 802 concentrations concentration NNS 803 810 ranging range VBG 811 815 from from IN 816 822 10(-9) 10(-9) CD 823 825 to to TO 826 832 10(-6) 10(-6) CD 833 835 M. M. NNP 836 839 The the DT 840 848 inactive inactive JJ 849 858 precursor precursor NN 858 859 , , , 860 884 lyso-platelet-activating lyso-platelet-activating JJ 885 891 factor factor NN 891 892 , , , 893 895 at at IN 896 897 a a DT 898 911 concentration concentration NN 912 914 as as RB 915 919 high high JJ 920 922 as as IN 923 929 10(-7) 10(-7) CD 930 931 M M NNP 932 935 had have VBD 936 938 no no DT 939 945 effect effect NN 946 948 on on IN 949 952 any any DT 953 955 of of IN 956 959 the the DT 960 968 membrane membrane NN 969 982 phospholipids phospholipid NNS 982 983 . . . 984 986 We we PRP 987 991 also also RB 992 996 show show VBP 997 1001 that that IN 1002 1021 platelet-activating platelet-activating JJ 1022 1028 factor factor NN 1029 1033 from from IN 1034 1041 10(-12) 10(-12) CD 1042 1044 to to TO 1045 1051 10(-6) 10(-6) CD 1052 1053 M M NNP 1054 1061 induced induce VBD 1062 1067 rapid rapid JJ 1068 1071 and and CC 1072 1083 significant significant JJ 1084 1093 elevation elevation NN 1094 1096 in in IN 1097 1110 intracellular intracellular JJ 1111 1118 calcium calcium NN 1119 1125 levels level NNS 1125 1126 , , , 1127 1134 whereas whereas IN 1135 1159 lyso-platelet-activating lyso-platelet-activating JJ 1160 1166 factor factor NN 1167 1170 was be VBD 1171 1176 again again RB 1177 1188 ineffective ineffective JJ 1188 1189 . . . 1190 1192 We we PRP 1193 1200 further further RB 1201 1212 demonstrate demonstrate VBP 1213 1216 the the DT 1217 1223 impact impact NN 1224 1226 of of IN 1227 1246 platelet-activating platelet-activating JJ 1247 1253 factor factor NN 1254 1261 binding bind VBG 1262 1264 to to TO 1265 1266 B B NNP 1267 1272 cells cell NNS 1273 1275 by by IN 1276 1285 measuring measure VBG 1286 1305 platelet-activating platelet-activating JJ 1306 1312 factor factor NN 1313 1320 induced induced JJ 1321 1332 arachidonic arachidonic JJ 1333 1337 acid acid NN 1338 1345 release release NN 1346 1349 and and CC 1350 1375 5-hydroxyeicosatetraenoic 5-hydroxyeicosatetraenoic JJ 1376 1380 acid acid NN 1381 1391 production production NN 1391 1392 . . . 1393 1401 Moreover moreover RB 1401 1402 , , , 1403 1422 platelet-activating platelet-activating JJ 1423 1429 factor factor NN 1430 1433 was be VBD 1434 1441 capable capable JJ 1442 1444 of of IN 1445 1453 inducing induce VBG 1454 1467 transcription transcription NN 1468 1470 of of IN 1471 1474 the the DT 1475 1482 nuclear nuclear JJ 1483 1498 proto-oncogenes proto-oncogene NNS 1499 1504 c-fos c-fos NN 1505 1508 and and CC 1509 1514 c-jun c-jun NN 1514 1515 . . . 1516 1523 Finally finally RB 1524 1526 we we PRP 1527 1535 explored explore VBD 1536 1539 the the DT 1540 1548 possible possible JJ 1549 1553 role role NN 1554 1556 of of IN 1557 1582 5-hydroxyeicosatetraenoic 5-hydroxyeicosatetraenoic JJ 1583 1587 acid acid NN 1588 1590 as as IN 1591 1592 a a DT 1593 1602 regulator regulator NN 1603 1605 of of IN 1606 1617 arachidonic arachidonic JJ 1618 1622 acid acid NN 1623 1633 liberation liberation NN 1634 1647 demonstrating demonstrate VBG 1648 1652 that that IN 1653 1663 endogenous endogenous JJ 1664 1678 5-lipoxygenase 5-lipoxygenase NN 1679 1687 activity activity NN 1688 1697 modulates modulate VBZ 1698 1717 platelet-activating platelet-activating JJ 1718 1724 factor factor NN 1725 1732 induced induced JJ 1733 1744 arachidonic arachidonic JJ 1745 1749 acid acid NN 1750 1757 release release NN 1758 1765 perhaps perhaps RB 1766 1772 acting act VBG 1773 1775 at at IN 1776 1779 the the DT 1780 1785 level level NN 1786 1788 of of IN 1789 1802 phospholipase phospholipase NN 1803 1805 A2 a2 NN 1805 1806 . . . 1807 1809 In in IN 1810 1817 summary summary NN 1817 1818 , , , 1819 1838 platelet-activating platelet-activating JJ 1839 1845 factor factor NN 1846 1848 is be VBZ 1849 1854 shown show VBN 1855 1859 here here RB 1860 1862 to to TO 1863 1867 have have VB 1868 1869 a a DT 1870 1876 direct direct JJ 1877 1880 and and CC 1881 1889 profound profound JJ 1890 1896 effect effect NN 1897 1899 on on IN 1900 1901 a a DT 1902 1906 pure pure JJ 1907 1908 B B NNP 1909 1913 cell cell NN 1914 1918 line line NN 1918 1919 . . .